Rosuvastatin has demonstrated efficacy in reducing cardiovascular risk through broad clinical experience. Specifically: 1) The METEOR study showed that rosuvastatin slowed the progression of atherosclerosis, while ENHANCE found no significant difference between simvastatin and simvastatin plus ezetimibe. 2) Real-world studies like PEPI and a US study found rosuvastatin use was associated with a 20-40% reduced risk of cardiovascular events compared to other statins. 3) The ASTEROID trial used intravascular ultrasound to demonstrate that rosuvastatin significantly reduced coronary atheroma burden over 18 months.

1. Assurance of
Cardiovascular Risk Reduction
comes from broad Clinical Experience

2. Is Lower Better?
La relation entre le LDL-c et les evenements cardiovasculaires
Rosenson RS. Exp Opin Emerg Drugs 2004;9(2):269-279, LaRosa JC et al. N Engl J Med 2005;352:1425-1435.
LDL-C atteint mg/dL (mmol/L)
WOSCOPS – Pl
AFCAPS - Pl
ASCOT - Pl
AFCAPS - Rx WOSCOPS - Rx
ASCOT - Rx
4S - Rx
HPS - Pl
LIPID - Rx
4S - Pl
CARE - Rx
LIPID - Pl
CARE - Pl
HPS - Rx
0
5
10
15
20
25
30
40
(1.0)
60
(1.6)
80
(2.1)
100
(2.6)
120
(3.1)
140
(3.6)
160
(4.1)
180
(4.7)
6
Prevention secondaire
Prevention Primaire
Rx - Statin therapy
Pl – Placebo
Pra – pravastatin
Atv - atorvastatin
200
(5.2)
PROVE-IT - Pra
PROVE-IT – Atv
TNT – Atv10
TNT – Atv80
INTRO
STELLAR
PEPI
METEOR
ASTEROID
JUPITER

3. La moitié des patients n’atteignent pas leur objectif
lipidique
EUROASPIRE II:51%
des patients n’ont pas
atteint l’objectif
Patients sous
hypolipémiants qui
ont atteint leur
objectif
50%
25% 75% 100%
EUROASPIRE II: Atteinte d’objectif
cholesterol total
51%
Lipid management assessed in 5556 patients with CHD at least 6 months
after discharge who qualify for treatment
EUROASPIRE II. Eur Heart J 2001;22:554–572

4. La relation entre le taux du LDL-c et HDL ET LE RISUE
CARDIOVASCULAIRE
Third Report of the NCEP Expert Panel. NIH Publication No. 01-3670 2001.
http://hin.nhlbi.nih.gov/ncep_slds/menu.htm
1% decrease
in LDL-C reduces
CHD risk by
1%
1% increase
in HDL-C reduces
CHD risk by
1-3%
INTRO
STELLAR
PEPI
METEOR
ASTEROID
JUPITER

5. Rosuvastatin
Atorvastatin
Simvastatin
Pravastatin
*p<0.002 vs atorvastatin 10 mg; simvastatin 10, 20, 40 mg; pravastatin 10, 20, 40 mg
†p<0.002 vs atorvastatin 20, 40 mg; simvastatin 20, 40, 80 mg; pravastatin 20, 40 mg
‡p<0.002 vs atorvastatin 40 mg; simvastatin 40, 80 mg; pravastatin 40 mg
*
X
X
X
–60
–50
–40
–30
–20
–10
0
Dose, mg (log scale)
10 20 40 80
X
X
n=648
n=473
n=634
n=485
†
‡
Change
in
LDL-C
from
baseline
(%)
Rosuvastatin versus Comparators:
LDL-C Efficacy Across the Dose Range
The STELLAR Study
INTRO
STELLAR
PEPI
METEOR
ASTEROID
JUPITER
Jones PH et al. Am J Cardiol 2003;92:152–160

6. Rosuvastatin versus other statins - change in HDL-C
The STELLAR Study
*p<0.002 vs pravastatin 10 mg
†p<0.002 vs atorvastatin 20, 40, 80 mg; simvastatin 40 mg; pravastatin 20, 40 mg
‡p<0.002 vs atorvastatin 40, 80 mg; simvastatin 40 mg; pravastatin 40 mg
Observed data in ITT population
10 20 40
3.2
4.4
5.6
10 20 40 80
10 20 40
0
2
4
6
8
10
12
5.7
4.8
4.4
2.1
*
7.7
†
9.5
‡
9.6
10 20 40 80
5.3
6.0
5.2
6.8
Dose (mg)
Rosuvastatin
Atorvastatin
Pravastatin
Simvastatin
Change
in
HDL-C
from
baseline
(%)
INTRO
STELLAR
PEPI
METEOR
ASTEROID
JUPITER
Jones PH et al. Am J Cardiol 2003;92:152–160

7. CV Risk Reduction –
Head-to- head comparison In ‘’Real Life’’
All statin users between January 2000 and September 2005
rosuvastatin
N = 8,088
atorvastatin
N = 25,777
simvastatin
N = 27,752
pravastatin
N = 14,530
Exclude:
• Established statin users (prior statin use in last 12 months)
• patients with CV event in previous 12 months
• patients with <12 months history in PHARMO
• cerivastatin and fluvastatin users*
• Use of >1 statin simultaneously
• patients under 18
N = 76,147
Followed until first CV event or cessation of
initial statin use or loss to follow-up in the
database
* Cerivastatin was withdrawn from the market in 2002. There were too few fluvastatin users for any meaningful analyses
Heintjes et al, Current Medical Opinion and Research, July 2008 PEPI
INTRO
STELLAR
PEPI
METEOR
ASTEROID
JUPITER

8. Retrospective observational cohort study
Primary outcome: Cardiovascular (CV) Hospitalisations
Fatal and non-fatal ischaemic heart disease, myocardial
infarction (MI), fatal and non-fatal stroke, coronary and carotid
revascularisation
Secondary outcome
Hospitalisations for MI
Hazard ratios¶ with 95% confidence intervals calculated
Adjusted for patient characteristics, co-morbidities and co-
medications
*I.e. CV events counted whilst on original statin
¶ The ‘hazard ratio’ was the ratio of the incidence of CV events on rosuvastatin versus that on other
statins
CV Risk Reduction –
Head-to- head comparison In ‘’Real Life’’
PEPI
INTRO
STELLAR
PEPI
METEOR
ASTEROID
JUPITER
Heintjes et al, Current Medical Opinion and Research, July 2008

9. Primary Outcome
Rates of CV events were 28% lower on CRESTOR compared with other statins
0.4
0.6
0.8
1.0
1.2
1.4
CRESTOR vs. other
statins
CRESTOR (10.8 mg)
vs.
ATV (17.3 mg)
RSV better RSV worse
CRESTOR (10.8 mg)
vs.
SMV (22.1 mg)
CRESTOR (10.8 mg)
vs.
PRV (33.8 mg)
* A 95% CI that does not exceed 1 indicates a statistically significant hazard ratio
0.72 (0.56-0.94) *
0.83 (0.63-1.10) NS
0.71 (0.54-0.94) *
0.60 (0.45-0.80) *
Hazard ratios of CV were adjused for age, gender, nitrates, classic antihypertensives and diabetes
Adjusted hazard ratio of CV hospitalisations (95% CI)
28%
17%
29%
40%
Reductio
n in CV
events
PEPI
INTRO
STELLAR
PEPI
METEOR
ASTEROID
JUPITER
Heintjes et al, Current Medical Opinion and Research, July 2008

10. US Study
Patient selection
All statin users between August 2003 and December 2005
rosuvastatin
N = 45,510
atorvastatin
N = 196,523
simvastatin
N = 73,884
pravastatin
N = 25,055
Exclude:
•established statin users (prior statin use in last 12 months)
•serious non-CV disease or immunosuppression
•with <12 months history in database
•patients under 18
N = 395,056
Followed until: first CV event, switch to another statin therapy
or switch/add another lipid-lowering therapy or 90 days after
end of statin supply or loss to follow-up in the database
lovastatin
N = 45,483
fluvastatin
N = 8,584
INTRO
STELLAR
PEPI
METEOR
ASTEROID
JUPITER
Heintjes et al, Current Medical Opinion and Research, July 2008

11. US Study Results: Reduction in CV events
>=90 days
>=180 days
>=270 days
0.95 (0.84-1.08)
0.88 (0.74-1.05)
0.76 (0.59-0.97) ‡
RSV better Other statins† better
0.6
0.8
1.0
1.2
0.97 (0.86-1.08)
0.91 (0.78-1.06)
0.80 (0.64-1.00) ‡
MPR>0.8
MPR>0.8
MPR>0.8
‡ A 95% CI that does not exceed 1 indicates a statistically significant hazard ratio
Adjusted* hazard ratio of CV events (95% CI)
20%
Reductio
n in CV
events
In patients with higher compliance¶ and longer exposure times, a trend of a higher
decreased CV event rate with RSV as compared to other statins was found
INTRO
STELLAR
PEPI
METEOR
ASTEROID
JUPITER
N = 395,056
Heintjes et al, Current Medical Opinion and Research, July 2008

12. What about efficacy in atherosclerosis?
Which is the Most Effective Statin
in Regression of athersclerosis?
INTRO
STELLAR
PEPI
METEOR
ASTEROID
JUPITER

13. ENHANCE METEOR
Patients High-risk FH (n=720) Lower risk asymptomatic subjects at
low risk of CHD (n=984)
LDL-C Baseline LDL-C 319mg/dL;
8.3mmol/L
Mean baseline LDL-C 155mg/dL;
4mmol/L
CIMT
analysed
Mean change from baseline in
CIMT using composite measures
from the right + left far wall CCA,
carotid bulb and ICA
6 sites – far wall only
Max CIMT, based on 12 carotid artery
segments (near & far wall of the right
and left CCA, carotid bulb and ICA)
12 sites – near and far walls
Status Completed April ‘06, press release
14 Jan 08. Likely to jeopardise
presentation of results at ACC Mar
’08 (23 months later).
Completed May ’06, data at ACC Mar ’07
(10 months later)
Results No statistical difference in mean
CIMT (primary endpoint), or in
individual components of primary
endpoint, including CCA.
CRESTOR 40 mg slowed the rate of
progression of maximum CIMT vs
placebo ….and with significant
regression of CIMT in the CCA
ENHANCE vs METEOR
INTRO
STELLAR
PEPI
METEOR
ASTEROID
JUPITER
Kasteline J et al, NEJM April, 2008 Crouse J et al, JAMA, 2007

14. Time
(years)
-0.01
+0.01
0.00
+0.02
2
1
+0.03
Progression
Regression
P=NS
(CRESTOR vs. zero slope
Placebo
+0.0131 mm/yr
(n=252)
Rosuvastatin 40 mg
-0.0014 mm/yr
(n=624)
P<0.001
(CRESTOR vs. placebo)
Placebo; Change in CIMT (95% CI)
Rosuvastatin 40 mg; Change in CIMT (95% CI
METEOR primary endpoint:
Rate of change of maximum IMT at 12 carotid sites Rosuvastatin vs placebo
Crouse JR III, et al. JAMA 2007;297 (12):1344–1353
INTRO
STELLAR
PEPI
METEOR
ASTEROID
JUPITER
48%
reduction LDL-C
8%
Increase HDL-C

15. ENHANCE results
Time
(years)
-0.01
+0.01
0.00
+0.02
+0.03
Primary
Endpoint
Change
in
mean
IMT
at
6
carotid
sites
(mm)
SMV 80 + EZE
+0.0111 mm
p=0.29 (ns)
SMV 80
+0.0058 mm
• 720 patients with familial hypercholesteraemia
• 1° endpoint: Absolute change in mean cIMT
• Measured at 6 carotid sites
• Most patients established statin users
2
1
Ezetimibe/simvastatin 10/80mg showed no significant difference to
simvastatin 80mg on the primary endpoint (mean CIMT), on any component
of the primary endpoint, or on any of the secondary imaging endpoints
INTRO
STELLAR
PEPI
METEOR
ASTEROID
JUPITER
Kasteline J et al, NEJM April, 2008

16.  ENHANCE failed to meet its primary and secondary endpoints
and showed that adding ezetimibe to simvastatin provides no
benefit on the treatment of atherosclerosis
 CRESTOR has the proven efficacy to lower LDL-C, raise
HDL-C, and has been shown to slow the progression of
atherosclerosis at any stage of the disease
 CRESTOR significantly slowed the progression of atherosclerosis
in the METEOR study (which employed very similar methodology
to ENHANCE). These results were pivotal to achieving the
unique atherosclerosis indication granted by US FDA
Summary : METEOR & ENHANCE Results

17. A Study To evaluate the Effect of
Rosuvastatin On Intravascular
ultrasound-Derived coronary
atheroma burden
Nissen S et al. JAMA 2006;295 (13):1556-1565;
Ballantyne C et al. Circulation 2008 DOI: 10.1161/CIRCULATIONAHA.108.773747.
ASTEROID used intravascular ultrasound (IVUS) and
quantitative coronary angiography (QCA) to evaluate the effect
of rosuvastatin (CRESTOR™) on atherosclerotic disease in
patients with coronary artery disease (CAD)
INTRO
STELLAR
PEPI
METEOR
ASTEROID
JUPITER

18. Lumen
area
EEM area
Atheroma area
Ultrasound Determination of Atheroma Area
Precise planimetry of EEM and lumen borders
with calculation of atheroma cross-sectional area
INTRO
STELLAR
PEPI
METEOR
ASTEROID
JUPITER

19. Example of regression of
atherosclerosis with
rosuvastatin in ASTEROID,
measured by IVUS
Images courtesy of Cleveland
Clinic Intravascular Ultrasound
Core Laboratory
Effects of Rosuvastatin on intravascular ultrasound (IVUS)
- derived coronary artery atheroma burden The ASTEROID study
INTRO
STELLAR
PEPI
METEOR
ASTEROID
JUPITER
53%
reduction LDL-C
14%
Increase HDL-C

20. 2
The relationship between mean LDL-C and change in
percent atheroma volume (PAV) in IVUS studies†
Change in
Percent
Atheroma
Volume*
(%)
1 Nissen S et al. N Engl J Med 2006;354:1253-1263. 2 Tardif J et al. Circulation 2004;110:3372-3377.
3 Nissen S et al. JAMA 2006;295 (13):1556-1565 4 Nissen S et al. JAMA 2004;292: 2217–2225.
5 Nissen S et al. JAMA 2004; 291:1071–1080
-1
-0.5
0
0.5
1
1.5
50 60 70 80 90 100 110 120
A-Plus2
placebo
ACTIVATE1
placebo
CAMELOT4
placebo
REVERSAL5
pravastatin
REVERSAL5
atorvastatin
Mean LDL-C (mg/dL)
Progression
Regression
ASTEROID3
rosuvastatin
INTRO
STELLAR
PEPI
METEOR
ASTEROID
JUPITER

21. Change in Percent Diameter Stenosis vs
On-Treatment LDL-C in QCA Trials
* ASTEROID - rosuvastatin; MAAS - simvastatin; CCAIT - lovastatin; MARS – lovastatin;
LCAS - fluvastatin; PLAC I - pravastatin
40 60 80 100 120 140 160 180
-1
-0.8
-0.6
-0.4
-0.2
0
0.2
0.4
0.6
0.8
1
1.2
1.4
MARS
MAAS
PLAC I
LCAS
PLAC I
CCAIT
LCAS
MAAS
MARS
On-Treatment LDL-C (mg/dL)
CCAIT
Placebo
Statin*
Progression
Regression
Nissen S et al. JAMA 2006;295 (13):1556-1565;
Ballantyne C et al. Circulation 2008 DOI: 10.1161/CIRCULATIONAHA.108.773747.
INTRO
STELLAR
PEPI
METEOR
ASTEROID
JUPITER
ASTEROID3
rosuvastatin

22. Atherosclerosis is the underlying cause of heart disease - the
World’s number one killer
Rosuvastatin is the only statin to show regression of
coronary atherosclerosis in a major clinical study
In ASTEROID, two imaging modalities that measure different
parameters and focus on different segments of the coronary
arteries have demonstrated concordant improvements in both
IVUS measurements of atheroma volume and angiographic
measurements of lumen dimension consistent with regression
of atherosclerosis with intensive rosuvastatin therapy
CRESTOR Clinical Perspective in Atherosclerosis
METEOR ASTEROID
DISEASE PROGRESSION
OVER TIME
EARLY
DISEASE
ESTABLISHED
DISEASE
US FDA approval for atherosclerosis as an
indication- Nov. 2007
INTRO
STELLAR
PEPI
METEOR
ASTEROID
JUPITER

23. CRESTOR - Withdrawals due to Adverse Events
Percentage of patients with an adverse event
leading to withdrawal
0
2
4
6
8
rosuvastatin simvastatin pravastatin
1
3
5
7
2.9%
2.5% 2.5%
(n=3074) (n=1457) (n=1278)
3.2%
atorvastatin
(n=2899)
10–40 mg
10–80 mg
10–80 mg
10–40 mg
Brewer HB. Am J Cardiol 2003;92(Suppl):23K–29K
Shepherd J et al. Am J Cardiol 2004;94:882-888

24. CRESTOR – Liver Effects
ALT >3 × ULN: Frequency by LDL-C Reduction
0.0
0.5
1.0
1.5
2.0
2.5
3.0
20 30 40 50 60 70
LDL-C reduction (%)
Fluvastatin (20, 40, 80 mg)
Rosuvastatin (10, 20, 40 mg)
Lovastatin (20, 40, 80 mg)
Atorvastatin (10, 20, 40, 80 mg)
Simvastatin (40, 80 mg)
Occurrence
of
ALT
>3×ULN
(%)
Persistent elevation is elevation to >3 x ULN on 2 successive occasions
Brewer HB. Am J Cardiol 2003;92(Suppl):23K–29K

25. CRESTOR - Muscle Effects
CK >10 x ULN: Frequency by LDL-C Reduction
Brewer HB. Am J Cardiol 2003;92(Suppl):23K–29K
0.0
0.5
1.0
1.5
2.0
2.5
3.0
20 30 40 50 60 70
LDL-C reduction (%)
Occurrence
of
CK
>10
×
ULN
(%)
Cerivastatin (0.2, 0.3, 0.4, 0.8 mg)
Rosuvastatin (10, 20, 40 mg)
Pravastatin (20, 40 mg)
Atorvastatin (10, 20, 40, 80 mg)
Simvastatin (40, 80 mg)

26. Justification for the Use of statins in
Primary prevention: an Intervention
Trial Evaluating Rosuvastatin
CV Risk Reduction –CRESTOR Outcome Study
Objective: The primary objective of the JUPITER study is to investigate
whether long-term treatment with rosuvastatin 20 mg decreases the rate
of first major cardiovascular events compared with placebo in patients with
low LDL-C but with increased risk as identified by elevated CRP levels
Ridker PM et al. Am J Cardiol 2007; 100: 1659–1664.
INTRO
STELLAR
PEPI
METEOR
ASTEROID
JUPITER

27. 20%
Reduction
Mortality
44%
Reduction
CV events
48%
Reduction
Stroke
47%
Reduction
Unstable
angina
CV Risk Reduction –CRESTOR Outcome Study
INTRO
STELLAR
PEPI
METEOR
ASTEROID
JUPITER
47%
Reduction
Combined
CV risk
54%
Reduction
Heart
attack

28. Landmark Statin Trial - Highlights
Trial Year
published
Population Treatment % LDL-
C
RRR*
4S 1994 High cholesterol
CHD
S 20-40 mg -35% -34%
WOSCOPS 1995 High cholesterol
No CHD
P 40 mg -26% -31%
CARE 1996 Average cholesterol
CHD
P 40 mg -32% -24%
AFCAPS/
TexCAPS
1998 Average cholesterol,
low HDL-C
No CHD
L 20-40 mg -25% -37%
HPS 2002 Average cholesterol
CHD or a CHD risk
equivalent
S 40 mg -29% -24%
JUPITER 2008 Low to normal LDL-C R20 -50% -44%
*Relative risk of experiencing a major CV event
INTRO
STELLAR
PEPI
METEOR
ASTEROID
JUPITER

29. Lipids
CRP
Tolerability
Lipids
CRP
Tolerability
HbA1C
Placebo
run-in
1
–6
2
–4
3
0
4
13
Final
3–4 y
6-monthly
Randomisation Lipids
CRP
Tolerability
Rosuvastatin 20 mg (n~7500)
Placebo (n~7500)
Lead-in/
eligibility
No history of CAD
men ≥50 yrs
women ≥60 yrs
LDL-C <130 mg/dL
CRP ≥2.0 mg/L
CAD=coronary artery disease; LDL-C=low-density lipoprotein cholesterol; CRP=C-reactive protein; HbA1c=glycated haemoglobin
CV Risk Reduction –CRESTOR Outcome Study
Ridker PM et al. Am J Cardiol 2007; 100: 1659–1664.
INTRO
STELLAR
PEPI
METEOR
ASTEROID
JUPITER

30. Randomised (n=17,802)
mmol/L mg/dL
Total cholesterol 4.79 185
LDL-C 2.79 108
HDL-C 1.27 49
nonHDL-c 3.47 134
Triglycerides 1.33 118
Glucose 5.2 94
hsCRP, mg/L 4.3
HbA1c, % 5.7
Values expressed as median (interquartile range). For hsCRP, values are the mean of the screening and randomization visits.
LDL-C=low-density lipoprotein cholesterol; HDL-C=high-density lipoprotein cholesterol; hsCRP=median high sensitivity C-
reactive protein; HbA1c=glycosylated haemoglobin
Ridker PM et al. Am J Cardiol 2007; 100: 1659–1664.
Laboratory parameters at baseline
INTRO
STELLAR
PEPI
METEOR
ASTEROID
JUPITER

31. 0
1
2
3
4
5
6
7
8
9
0 1 2 3 4 5
Years
Placebo
Rosuvastatin 20 mg
JUPITER - Primary Endpoint
Percent
of
patients
with
primary
endpoint
Number at risk
RSV 8901 8412 3893 1353 538 157
Placebo 8901 8353 3872 1333 531 174
Hazard Ratio 0.56
(95% CI 0.46-0.69)
P<0.00001
NNT for 2y = 95
5y* = 25
44%
Reduction
Time to first occurrence of a CV death, non-fatal stroke, non-fatal
MI, unstable angina or arterial revascularization
INTRO
STELLAR
PEPI
METEOR
ASTEROID
JUPITER

32. JUPITER - Total Mortality
Death from any cause
0
1
2
3
4
5
6
7
0 1 2 3 4 5
Years
Placebo
Rosuvastatin 20mg
Percent
total
mortality
Number at risk
RSV 8901 8787 4312 1602 676 227
Placebo 8901 8775 4319 1614 681 246
Hazard Ratio 0.80
(95% CI 0.67-0.97)
p=0.02 20%
Reduction
INTRO
STELLAR
PEPI
METEOR
ASTEROID
JUPITER

33. JUPITER - Primary Endpoint Components
Primary Endpoint 251 (1.36) 142 (0.77) 0.56 0.46-0.69 <0.001*
(Time to first occurrence of CV death, MI, stroke, unstable angina, arterial revascularisation)
Non-fatal MI 62 (0.33) 22 (0.12) 0.35 0.22-0.58 <0.001*
Fatal or non-fatal MI 68 (0.37) 31 (0.17) 0.46 0.30-0.70 0.0002
Non-fatal stroke 58 (0.31) 30 (0.16) 0.52 0.33-0.80 0.003
Fatal or non-fatal stroke 64 (0.34) 33 (0.18) 0.52 0.34-0.79 0.002
Arterial Revascularization 131 (0.71) 71 (0.38) 0.54 0.41-0.72 <0.0001
Unstable angina† 27 (0.14) 16 (0.09) 0.59 0.32-1.10 0.09
CV death, stroke, MI 157 (0.85) 83 (0.45) 0.53 0.40-0.69 <0.001*
Revascularization
or unstable angina 143 (0.77) 76 (0.41) 0.53 0.40-0.70 <0.001*
Placebo Rosuvastatin HR 95% CI p-value
[n=8901] [n=8901]
n (rate**) n (rate**)
** Rates are per 100 person years; † Hospitalisation due to unstable angina; *Actual p-value was < 0.00001
INTRO
STELLAR
PEPI
METEOR
ASTEROID
JUPITER

34. Tolerability and safety data
Adverse Events, (%)
Any serious adverse event 15.5 15.2 0.60
Muscle weakness, stiffness, pain 15.4 16.0 0.34
Myopathy 0.1 0.1 0.82
Rhabdomyolysis 0.0 <0.1* ----
Newly diagnosed cancer 3.5 3.4 0.51
Death from cancer 0.7 0.4 0.02
Gastrointestinal disorders 19.2 19.7 0.43
Renal disorders 5.4 6.0 0.08
Bleeding 3.1 2.9 0.45
Hepatic disorders 2.1 2.4 0.13
Other events, (%)
Newly diagnosed diabetes** 2.4 3.0 0.01
Haemorrhagic stroke 0.1 0.1 0.44
Placebo Rosuvastatin p-value
[n=8901] [n=8901]
*Occurred after trial completion; **physician reported newly diagnosed diabetes
INTRO
STELLAR
PEPI
METEOR
ASTEROID
JUPITER

35. Laboratory Safety Data
Laboratory Values, N (%)
Serum creatinine‡ 10 (0.10) 16 (0.20) 0.24
ALT > 3 x ULN# 17 (0.20) 23 (0.30) 0.34
Glycosuria† 32 (0.40) 36 (0.50) 0.64
Laboratory Values, median values (IQR)
GFR*, (mL/min/1.73m2) 66.6 (58.8-76.2) 66.8 (59.1-76.5) 0.02
% HbA1c** 5.8 (5.6-6.1) 5.9 (5.7-6.1) 0.001
Fasting plasma glucose**, (mg/dL) 98 (90-106) 98 (91-107) 0.12
Placebo Rosuvastatin p-value
[n=8901] [n=8901]
GFR = Glomerular filtration rate, HbA1c = Haemoglobin A1c
# on consecutive visits, ‡ >100% increase from baseline, *at 12 months, **at 24 months, †>trace at 12 months
INTRO
STELLAR
PEPI
METEOR
ASTEROID
JUPITER

36. JUPITER – summary and perspectives
The JUPITER study included patients with low to normal LDL-C who were
at increased CV risk as identified by elevated CRP levels and who did not require
statin treatment based on current treatment guidelines
A 44% reduction in the primary endpoint of major cardiovascular events
(composite of: CV death, MI, stroke, unstable angina, arterial revascularisation)
was observed in patients who received rosuvastatin 20 mg compared with
placebo (p< 0.00001)
A 20% reduction in total mortality was observed in patients who received
rosuvastatin 20 mg compared with placebo (p=0.02), a unique finding for statins
in a population without established CHD
In JUPITER, long-term treatment with rosuvastatin 20 mg was well tolerated
in nearly 9000 study participants
There was no difference between treatment groups for muscle weakness,
cancer, haematological disorders, gastrointestinal, hepatic or renal systems
The results from JUPITER highlight the importance of highly effective
statin treatment for these patients with an increased risk of CV disease
INTRO
STELLAR
PEPI
METEOR
ASTEROID
JUPITER

37. Assurance of
Cardiovascular Risk Reduction
comes from broad Clinical Experience
Best in class
HDL-C increase, and LDL-C
decrease
1
PEPI 2
Nearly 500,000 a million
patients in real life, have
shown CRESTOR is superior
in CV risk reduction as
compared to all statins
First statin to show..treating
dyslipidemia with Crestor halts the
progression of atherosclerosis in low
risk patients leading to US FDA
approval in atherosclerosis
indication
3
4 out of 5 patients showed coronary
plaque regression in patients with
established CHD
4
First positive outcome on
CRESTOR – Study halted
because of unequivocal
superiority in cardiovascular
morbidity and mortality
5
CRESTOR
- Offers Comprehensive Lipid Management